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AbSTrACT
Objective To prospectively investigate whether 
differences in pulmonary vasculature exist in systemic 
sclerosis (ssc) and how they are distributed in patients 
with different pulmonary function.
Methods seventy- four patients with ssc undergoing 
chest CT scan for interstitial lung disease (ilD) screening 
or follow- up were prospectively enrolled. a thorough 
clinical, laboratory and functional evaluation was 
performed the same day. Chest CT was spirometry gated 
at total lung capacity and images were analysed by two 
automated software programs to quantify emphysema, 
ilD patterns (ground- glass, reticular, honeycombing), and 
pulmonary vascular volume (PVV). Patients were divided 
in restricted (FVC% <80, Dlco%<80), isolated Dlco% 
reduction (iDlco- FVC%≥80, Dlco%<80) and normals 
(FVC%≥80, Dlco%≥80). spearman ρ, Mann- Whitney 
tests and logistic regressions were used to assess for 
correlations, differences among groups and relationships 
between continuous variables.
results absolute and lung volume normalised PVV 
(PVV/lV) correlated inversely with functional parameters 
and positively with all ilD patterns (ρ=0.75 with ground 
glass, ρ=0.68 with reticular). PVV/lV was the only 
predictor of Dlco at multivariate analysis (p=0.007). 
Meanwhile, the reticular pattern prevailed in peripheral 
regions and lower lung thirds, PVV/lV prevailed in central 
regions and middle lung thirds. iDlco group had a 
significantly higher PVV/lV (2.2%) than normal (1.6%), 
but lower than restricted ones (3.8%).
Conclusions Chest CT in ssc detects a progressive 
increase in PVV/lV as Dlco decreases. Redistribution 
of perfusion to less affected lung regions rather than 
angiogenesis nearby fibrotic lung may explain the results. 
Further studies to ascertain whether the increase in PVV/
lV reflects a real increase in blood volume are needed.
InTrOduCTIOn
Systemic sclerosis (SSc) is a multisystem connective 
tissue disease that may affect the lung with inter-
stitial lung disease (ILD) and/or pulmonary arterial 
hypertension (PAH).1 To detect lung involvement, 
pulmonary function tests (including forced vital 
capacity (FVC) and diffusing capacity for carbon 
monoxide (DLco)) and ILD visual analysis on chest 
CT are the basis for determining baseline disease 
severity, prognosis and evolution.2 3
Recent technological advances in CT image post 
processing permitted non- invasive and fully auto-
mated quantitative analysis of pulmonary vascula-
ture, without the use of contrast media and exposure 
to repeated ionising radiation during injection.4–7 
Nonetheless, quantitative imaging requires stan-
dardised acquisition protocols and quality certi-
fied and validated image analysis methodology to 
ensure accuracy and precision of the quantitative 
information provided.8 Among the sources of varia-
tion in quantifying chest radiological features, lung 
volume at acquisition time is the most relevant. Few 
studies used spirometry- gated CT to account for 
this possible source of variation.9–12
The main objectives of the present study were to 
investigate (1) the correlations between pulmonary 
vascular and functional parameters, (2) whether 
differences in pulmonary vascular parameters exist 
in SSc and (3) how they are distributed among 
patients with different pulmonary functional 
parameters by using a non- invasive fully automated 
methodology on spirometry- gated chest CT scans.
Key messages
 ► Patients with systemic sclerosis (SSc) may have 
a heterogeneous spectrum of gas exchange 
and pulmonary function patterns, but whether 
differences in pulmonary vasculature exist 
among them is not known.
 ► Our study demonstrates that patients with SSc 
have different patterns of pulmonary vascular 
changes at spirometry- gated CT scans, with 
pulmonary vascular volume significantly 
increased in patients with DLco% reduction and 
even more in those with a restrictive pattern.
 ► Meanwhile, the reticular pattern was 
significantly higher in the peripheral regions 
and in the lower lung third; the pulmonary 
vascular volume was significantly higher in the 
central regions and in the middle lung third.
 ► Interstitial lung disease patterns and pulmonary 
vascular volume as quantified at CT may be 
considered as biomarkers of disease for future 
trials assessing at the therapeutic effect of 
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MATerIAlS And MeTHOdS
From January to December 2018, patients with SSc classified 
according to American College of Rheumatology/European 
League Against Rheumatism 201313 undergoing chest CT for 
screening or follow- up of ILD were prospectively enrolled in the 
study. Patients with lung masses and those unable or unwilling to 
provide informed consent were excluded. All participants gave 
their written informed consent.
Clinical and Functional evaluation
Demographic and clinical data, serology and laboratory, instru-
mental and functional data were collected. FVC/DLco ratio was 
derived.3 Patients self- assessment features (disability index—
Scleroderma Health Assessment Questionnaire; Visual Analogic 
Scales (VAS); quality of life index as 5- level EQ- 5D versionEQ- 
5D- 5L14) were collected from medical charts, within a 3 months 
maximum range for modifiable variables.
radiological evaluation
Along with functional evaluation, patients underwent unen-
hanced chest CT in the same day. Chest CT scans were acquired 
on the same scanner (SIEMENS Sensation 16, Erlangen, 
Germany) with a fixed protocol: 120 kV, 0.5 s rotation time, 
pitch 1.0. Patients were instructed on how to perform the respi-
ratory manoeuvre lying supine during the scan acquisition by 
the same pulmonologist (GC) who did also the functional eval-
uation. Patients were instructed to inspire as deeply as possible 
and to hold their breath under supervision of the curve at the 
portable spirometry (Micro Medical, VyAire Medical, Cali-
fornia, USA). The curve was repeated at least three times to 
ensure consistency among volumes at maximal inspiration (total 
lung capacity (TLC)). If the TLC values were consistent, then 
chest CT scan was acquired at the desired volume. The portable 
spirometer was hanged on a fixed C- arm and connected through 
USB wire to the laptop with the spirometric software.
CT raw data were processed to create two sets of 1 mm 
thick axial slices: one using standard reconstruction algorithm 
(Convolution Kernel B35f) for quantitative analysis and one 
using a high- resolution reconstruction algorithm (Convolution 
Kernel B60f) for qualitative analysis.
CT images with standard reconstruction algorithm were post-
processed using two automated software programs dedicated to 
lung diseases.
Imbio LTA (based on CALIPER algorithm) was used to identify 
and quantify lung patterns through texture analysis, including 
normal lung, hyperlucencies, ground- glass, reticular and honey-
combing. The sum of ground- glass, reticular and honeycombing 
constituted the total ILD extent (ILD_Ext). Moreover, Imbio LTA 
identified and quantified the pulmonary vascular volume (PVV) 
in whole lungs and across lung vertical thirds.15 Its normalised 
value to lung volume (PVV/LV) was then derived.
Imbio LDA was used to quantify the low density areas (LDA), 
as both absolute and relative volumes, through densitometric 
analysis with the threshold at −950 HU that is considered 
consistent with emphysema extent.16 A variable called ‘true 
hyperlucency’ (TH) was derived from the difference between 
hyperlucencies and LDA.
data analysis
Absolute and relative frequencies were used to describe quali-
tative variables. Mean and SD were used to describe quantita-
tive variables. Spearman Rho correlation coefficient was used to 
compare radiological with functional and clinical variables.
Patients were divided according to FVC% and DLco% 
values in three groups using cut- offs reported in previous 
studies17 18: restricted (FVC%<80 and DLco%<80), isolated 
DLco% reduction (iDLco, FVC%≥80 and DLco%<80) and 
normals (FVC%≥80 and DLco%≥80). An arbitrary cut- off at 
70% for DLco% was also considered for comparison. Differ-
ences between groups were assessed by Mann- Whitney test. 
Kolmogorov- Smirnoff and Shapiro- Wilk tests were used to test 
for variables distribution. Univariate and multivariate regres-
sion analyses were performed to test the relationship between 
DLco%, PVV/LV and ILD patterns. The linear regression model 
with generalised estimating equation was used to test the rela-
tionship between ILD_Ext and PVV/LV across lung thirds. 
P<0.05 was deemed statistically significant. Data analysis was 
performed by using MedCalc V.16, SAS V.9.3 and Prism V.8.4.2 
(GraphPad Software, LLC).
reSulTS
Seventy- four patients composed the final population (65/74 
females—88%, median time from first non- Raynaud’s phenom-
enon duration 7 years); 3/77 were excluded for the presence 
of infection or bronchiectases at CT. Clinical, functional and 
radiological characteristics of the population are shown in 
table 1 (continuous variables) and table 2 (categorical variables). 
All patients showed a preserved right (tricuspid anular plane 
systolic excursion) and left cardiac (left ventricle ejection frac-
tion) systolic functions, with mean systolic pulmonary arterial 
pressure (sPAP) within upper level of normal ranges. Thirty- 
five to 54% of patients had iDLco, considering the cut- off of 
DLco reduction at 70 or 80%, respectively. Emphysema extent 
(%LDA) was greater than 6% in three patients and greater 
than 14% in one patient; two patients with higher %LDA were 
part of the iDLCO group, whereas the other two were among 
normals.
Correlations between clinical, functional and imaging 
parameters
Table 3 reports the correlations between vascular CT metrics 
and radiological patterns, functional and clinical- laboratory 
parameters. Vascular CT metrics (PVV and PVV/LV) showed an 
inverse correlation with functional parameters (FVC%, FEV1%, 
TLC% and DLco%) and CT patterns of normal lung, emphy-
sema (%LDA) and TH. Conversely, a strong positive correlation 
was found between vascular CT metrics and all ILD patterns, 
the highest with %ground glass (ρ=0.75). Among the clinical- 
laboratoristic parameters, PVV/LV correlated with those related 
to cardiovascular involvement (sPAP, N- terminal pro- brain 
natriuretic peptide, VAS digital ulcers) and to scores related to 
disease activity, disability and quality of life (VAS disease activity, 
Heart Assessment Questionnaire (HAQ), HAQ for walking, 
EQ- 5D- 5L).
Table 4 shows differences in vascular CT metrics according 
to clinical parameters. Patients with VEDOSS had a signifi-
cantly lower PVV/LV, whereas those with ACA or ATA posi-
tivity, elevated ESR or CRP, a late scleroderma pattern at 
nailfold videocapillaroscopy, and NYHA functional class ≥2 
had a significantly higher PVV/LV. At multivariate regression 
analysis, PVV/LV was the only predictive parameter for DLco 
(slope: −11.47±4.08; 95% CI −19.62 to −3.31; p=0.007). At 
univariate analysis, both reticular and PVV/LV were predictive 
for DLco (p=0.028 and p=0.019, respectively).
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Table 1 Clinical, functional and imaging characteristics of the 74 
systemic sclerosis included patients
Mean Sd
BMI 24.6 4.5
DLco % 65.8 18.9
DLco/AV 80.0 21.3
Kroghs 3.1 0.9
FVC % 101.1 24.8
FVC/DLco 1.6 0.7
FEV1 % 95.3 21.3
FEV1/FVC (%) 78.9 12.2
IC % 91.7 26.8
TLC % 94.5 18.3
6MWT (%) 79.3 7.7
SaO2 (%) 96.2 3.8
VAS Resp 30.4 31.9
mRSS 6.1 7.5
NYHA 1.5 0.8
sPAP (mm Hg) 29.0 9.3
TAPSE (mm) 22.4 4.7
LVEF (%) 61.9 5.8
RRI 0.68 0.07
Creatinine clearance (mg/dL/24 hours) 92 18
% Normal 85.3 13.6
% Ground glass 5.5 10.4
% Reticular 1.5 2.3
% Honeycombing 0.1 0.3
% TH 7.1 11.0
% LDA 1.1 3.3
MLA (HU) −820.3 126.5
LV (mL) 4587.0 1148.3
PVV (cm3) 99.4 35.9
PVV/LV (%) 2.3 1.2
PVV/LV RU central/peripheral (%) 2.8/0.6 1.1/0.7
PVV/LV RM central/peripheral (%) 3.6/0.7 1.3/0.9
PVV/LV RL central/peripheral (%) 4.7/1.7 3.7/2.4
PVV/LV LU central/peripheral (%) 2.5/0.5 1.0/0.9
PVV/LV LM central/peripheral (%) 4.0/0.9 1.8/1.3
PVV/LV LL central/peripheral (%) 4.5/2.3 4.5/3.0
AV, alveolar volume; BMI, body mass index; DLco, diffusion lung capacity for 
carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 
HU, Hounsfield Units; IC, inspiratory capacity; LDA, per cent of low density area; 
LL, left lower; LM, left middle; LU, left upper; LV, lung volume; LVEF, left ventricle 
ejection fraction; MLA, mean lung attenuation; mRSS, modified Rodnan Skin Score; 
6MWT, 6 min walking test; NYHA, New York Heart Association; PVV, pulmonary 
vascular volume; VAS Resp, Visual Analogic Scale for Dyspnoea; RL, right lower; RM, 
right middle; RRI, Renal Resistivity Index; RU, right upper; SaO2, arterial oxygen 
saturation; sPAP, systolic pulmonary arterial pressure; TAPSE, tricuspid anular plane 
systolic excursion; %TH, per cent of true hyperlucent; TLC, total lung capacity.
Table 2 Clinical presentation of the population studied (categorical 
variables)
n (%)
VEDOSS/diffuse/limited subset/sine scleroderma 13/34/26/1 (17.6/45.9/35.1/1.4)
ANA/ACA/ATA/ARA 74/20/31/5 (100/27.0/41.9/6.8)
Smoking history 31 (41.9)
Upper/lower gastrointestinal involvement 42/21 (56.8/28.4)
Digital ulcers 32 (43.2)
PAH 3 (4.0)
SRC 1 (1.4)
CRP >ULN 5 (6.8)
ESR >ULN 16 (21.6)
Restricted /iDLco/normals* 16/40/18 (21.6/54.0/24.3)
*Cut- offs considered at 80% for both forced vital capacity and diffusion lung 
capacity for carbon monoxide (DLco).
ACA, anticentromere antibodies; ANA, antinuclear antibodies; ARA, anti- RNA 
polymerase III antibodies; ATA, antitopoisomerase I antibodies; CRP, C- reactive 
protein; ESR, erythrocyte sedimentation rate; iDLco, isolated DLco reduction; PAH, 
pulmonary arterial hypertension; SRC, scleroderma renal crisis; ULN, upper limit of 
normal; VEDOSS, very early diagnosis of systemic sclerosis.
Table 3 Correlations between vascular CT metrics and parenchymal 
patterns, functional and clinical- laboratory parameters
PVV PVV/lV
rho P value rho P value
LV −0.12 – −0.57 ≤0.001
%Normal −0.53 ≤0.001 −0.60 ≤0.001
ILD_Ext 0.56 ≤0.001 0.73 ≤0.001
%Ground glass 0.52 ≤0.001 0.75 ≤0.001
%Reticular 0.51 ≤0.001 0.68 ≤0.001
%Honeycombing 0.36 ≤0.01 0.48 ≤0.001
%TH −0.30 <0.05 −0.48 ≤0.001
%LDA −0.21 – −0.30 <0.05
MLA 0.59 ≤0.001 0.67 ≤0.001
FVC% −0.26 <0.05 −0.40 ≤0.01
DLco% −0.18 – −0.29 <0.05
FEV1% −0.32 <0.05 −0.45 ≤0.01
FEV1/FVC 0.05 – 0.07 –
TLC% −0.36 ≤0.01 −0.62 ≤0.001
sPAP 0.10 – 0.45 ≤0.01
LVEF 0.17 – 0.23 –
24 hours urine protein −0.11 – −0.20 –
NT- proBNP 0.11 – 0.30 <0.05
RRI 0.24 – 0.19 –
mRSS 0.21 – 0.14 –
HAQ walking 0.12 – 0.40 ≤0.01
HAQ 0.15 – 0.44 ≤0.01
VAS dyspnoea 0.07 – 0.19 –
VAS Raynaud −0.04 – 0.15 –
VAS digital ulcers 0.23 – 0.50 ≤0.001
VAS disease activity 0.11 – 0.35 ≤0.01
EQ- 5D- 5L 0.19 – 0.43 ≤0.01
DLco, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 
s; FVC, forced vital capacity; HAQ, Heart Assessment Questionnaire; %HC, per cent 
honeycombing; ILD, interstitial lung disease; %LDA, per cent low- density area; LV, 
lung volume; LVEF, left ventricle ejection fraction; MLA, mean lung attenuation; 
mRSS, modified Rodnan Skin Score; NT- proBNP, N- terminal pro- brain natriuretic 
peptide; PVV, pulmonary vascular volume; RRI, Renal Resistive Index; sPAP, systolic 
pulmonary arterial pressure; %TH, per cent true hyperlucent; TLC, total lung 
capacity; VAS, Visual Analogic Scale.
Ild and vascular differences according to functional 
presentation and regional distribution
By using 80 as cut- off of FVC%, significant differences in ILD 
patterns were seen between patients with higher and lower 
FVC% values (all p<0.05, table 5). Differences in ILD patterns 
were similarly observed between groups with different DLco% 
by using a cut- off as lower as 70.
Table 6 shows differences in ILD patterns among the three 
functional groups (see online supplementary table 1 with 70% as 
cut- off for DLco% for comparison). Overall MLA and specific 
ILD patterns (ground glass, reticular, honeycombing) extent 
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Table 4 Distribution of vascular metrics at CT according to clinical, 
laboratory and instrumental features in patients with systemic 
sclerosis
PVV (cm3) PVV/lV (%)
Mean Sd P value Mean Sd P value
VEDOSS criteria
  Yes 86.86 37.18 – 1.69 0.68 0.009
  No 102.23 36.20 2.48 1.38
CRP elevation (>ULN)
  Yes 125.63 34.76 – 4.02 2.06 0.001
  No 95.44 35.30 2.14 1.10
ESR elevation (>ULN)
  Yes 124.05 46.77 0.001 3.47 2.02 <0.001
  No 90.80 29.06 1.97 0.79
ATA positivity
  Yes 106.48 42.27 – 2.50 1.57 0.001
  No 93.13 28.93 2.23 1.04
ACA positivity
  Yes 87.18 28.78 – 1.85 0.59 0.009
  No 103.05 37.20 2.48 1.37
Diffuse cutaneous 
subset
  Yes 108.11 38.62 – 2.65 1.57 –
  No 92.02 32.97 2.11 1.00
NYHA functional class
  ≥2 106.84 39.69 – 2.76 1.61 0.007
  <2 92.53 30.72 1.94 0.72
NVC scleroderma 
pattern
  Late 120.22 46.19 0.032 3.13 1.88 0.013
  Others 95.99 30.81 2.12 1.00
ACA, anticentromere antibody; ATA, antitopoisomerase I antibody; CRP, C- reactive 
protein; ESR, erythrocyte sedimentation rate; NVC, nailfold videocapillaroscopy; 
NYHA, New York Heart Association; PVV, pulmonary vascular volume; ULN, upper 
level of normal; VEDOSS, very early diagnosis of systemic sclerosis.
Table 5 Differences in quantitative CT parameters at diverse cut- off percentages of forced vital capacity (FVC) and diffusing capacity for carbon 
monoxide (DLco)
FVC <80% FVC≥80% P value dlco<80% dlco≥80% P value dlco<70% dlco≥70% P value
%Normal 82.7 (9.6) 86.2 (14.7) – 86.6 (12.7) 80.8 (15.8) – 84.1 (13.9) 86.4 (13.5) –
%Ground glass 10.3 (8.9) 2.4 (3.9) <0.001 5.0 (6.7) 3.9 (6.9) – 6.2 (7.5) 2.4 (4.8) 0.002
%Reticular 2.9 (2.9) 0.8 (1.3) <0.001 1.6 (2.1) 0.7 (0.9) – 1.9 (2.4) 0.6 (0.8) 0.007
%Honeycombing 0.4 (0.6) 0.1 (0.1) <0.001 0.2 (0.3) 0.1 (0.1) – 0.2 (0.4) 0.05 (0.2) 0.01
%TH 3.6 (6.8) 8.9 (12.1) – 5.4 (8.8) 14.1 (15.4) 0.050 6.3 (10.1) 9.2 (12.7) –
%LDA 1.2 (0.8) 5.5 (6.8) – 4.1 (6.1) 4.9 (6.9) – 1.3 (4.4) 1.0 (1.9) –
MLA (HU) −793.6 (35.8) −849.7 (30.3) <0.001 −833.2 (36.2) −843.3 (46.7) – −825.4 (40.0) −854.1 (32.9) 0.001
PVV 125.6 (39.1) 90.9 (26.9) <0.001 101.9 (34.8) 84.7 (19.4) 0.016 106.9 (38.3) 87.5 (20.5) 0.012
PVV/LV 3.8 (1.6) 2.0 (0.7) <0.001 2.5 (1.3) 1.7 (0.6) 0.002 2.8 (1.4) 1.8 (0.6) 0.001
Data are expressed as mean (SD). P values are reported only if significant (p<0.05).
%LDA, per cent low- density area; LV, lung volume; MLA, mean lung attenuation; PVV, pulmonary vascular volume; %TH, per cent true hyperlucent; TLC, total lung capacity.















FVC% 65.8 (10.8) 109.4 (17.5) 114.6 (18.3) *†
DLco% 51.8 (12.9) 59.2 (13.4) 89.4 (9.9) †‡
FVC/DLco 1.3 (0.4) 2.0 (0.7) 1.3 (0.3) *‡
Kroghs 3.7 (0.7) 2.8 (0.8) 3.7 (0.7) *‡
TLC % 71.3 (17.5) 96.4 (14.0) 107.9 (12.7) *†‡
RV % 76.3 (26.5) 94.8 (38.0) 109.0 (32.7) †
VC % 65.2 (28.4) 112.4 (19.5) 109.7 (44.5) *†
FEV1/FVC 80.2 (3.4) 77.5 (11.3) 74.8 (8.1)
LV (l) 3.6 (1.0) 4.5 (0.9) 5.3 (1.2) *†‡
%Normal 82.2 (9.5) 88.3 (13.4) 80.9 (16.8)
%Ground glass 10.2 (8.9) 3.1 (4.4) 0.9 (2.0) *†
%Reticular 3.1 (3.1) 1.1 (1.4) 0.4 (0.5) *†
%Honeycombing 0.5 (0.6) 0.1 (0.1) 0.1 (0.1) *†
%TH 4.0 (7.3) 6.0 (9.4) 16.0 (15.4) †‡
%LDA 0.1 (0.3) 1.4 (4.3) 1.7 (2.5) †
MLA (HU) −789.7 (35.7) −844.2 (28.6) −861.9 (32.5) *†
PVV (cm3) 127.2 (40.4) 95.2 (28.5) 82.2 (19.1) *†
PVV/LV (%) 3.8 2.2 1.6 *†‡
Data are expressed as mean (±SD). Significant differences (p<0.05) are reported as:
*Between groups restricted and iDLco.
†Between groups restricted and normals.
‡Between groups iDLco and normals.
DLco, diffusion lung capacity for carbon monoxide; FEV1, forced expiratory volume 
in 1 s; FVC, forced vital capacity; %LDA, per cent low- density area; LV, lung volume; 
MLA, mean lung attenuation; PVV, pulmonary vascular volume; RV, residual volume; 
%TH, per cent true hyperlucent; TLC, total lung capacity; VC, vital capacity.
were significantly higher in restricted than in iDLco and normal, 
while no differences in ILD patterns were found between the 
last two groups. No differences were found between groups in 
terms of LDA and TH. Conversely, all three groups had signif-
icant differences in lung volume as quantified on spirometry- 
gated CT (LV) and in vascular volumes (PVV and PVV/LV). 
Interestingly, the normal subset had lower vascular volumes than 
iDLCO and even more than the restricted subset. Kroghs index 
was significantly reduced only in the iDLCO subset. The online 
supplementary figure S1 shows that values of FVC/DLco were 
higher in the iDLCO group with respect to the others. TLC, VC 
and RV were all significantly reduced in the restricted group, 
whereas only TLC was reduced in the iDLco group.
Figure 1 summarises the differences in pulmonary vasculature 
among the three functional groups, demonstrating in 3D volume 
rendering that the PVV increases progressively from normals to 
iDLco and restricted groups.
Figure 2 shows the distribution of PVV/LV and the preva-
lent ILD patterns (ground- glass and reticular) across lung thirds 
(panel A) and between central and peripheral regions (panel B). 
The increase in reticular pattern towards lung bases was not 
coupled by a parallel increase in PVV/LV, with PVV/LV mainly 
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Figure 1 Three- dimensional volume rendering of pulmonary vasculature in three patients with SSc representative for each group of functional 
presentation. Pulmonary vessel volume increases progressively from normals to isolated diffusing capacity for carbon monoxide (iDLco) and restricted 
groups. Images were generated by using Horos V.3.3.5 on Imbio LTA data.
Figure 2 Distribution of pulmonary vascular volume (PVV) normalised on lung volume (LV) and interstitial lung disease (ILD) patterns across lung 
thirds (A) and between central and peripheral regions (B). The increase in reticular pattern towards lung bases is not coupled by a parallel increase in 
PVV/LV, with PVV/LV mainly located in the middle third. Note the significant differences in distribution of PVV/LV and reticular pattern between central 
and peripheral regions. ILD patterns and PVV are normalised for the volume of the corresponding third. ground- glass/lung volume (GG/LV) is not 
shown in panel B to emphasise the contraposition between reticular and PPV/LV.
located in the middle third. Meanwhile, the reticular pattern was 
significantly higher in the peripheral regions, the PVV/LV was 
significantly higher in the central regions (both p<0.001) and 
this was true for each lung third. A smaller association between 
PVV/LV and ILD_Ext was found in the lower third in respect 
to the other two- thirds (interaction slope: −0.0006; 95% CI 
−0.001 to −0.0001; p=0.013; see online supplementary figure 
2). It follows that an increase in ILD_Ext in the lower third was 
coupled by a smaller increase in PVV/LV than in the upper and 
middle thirds.
dISCuSSIOn
Our data clearly demonstrate that patients with SSc have 
different patterns of pulmonary vasculature changes, as shown 
by a non- invasive fully automated analysis of spirometry- gated 
chest CT scans. In particular, PVV was significantly increased in 
patients with DLco% reduction. The increase in PVV was even 
higher in patients presenting with a restrictive pattern at spirom-
etry. Furthermore, an increase in ILD_Ext in the lower third was 
coupled by a smaller increase in PVV/LV than in the upper and 
middle thirds.
In clinical practice, it is well known that patients with SSc, in 
relation to the stage of the disease, may have a heterogeneous 
spectrum of gas exchange and pulmonary function patterns, 
including normal, isolated DLco reduction, restrictive and 
obstructive patterns.17 In the current study, we found 35%–54% 
patients with iDLco according to the cut- off of DLco reduction 
used, around the upper limit of the range reported in literature 
(2%–40%, according to the cut- off used).17 19–22 In agreement 
with a previous study, no significant emphysema at CT was 
found in our patients cohort, as quantitatively assessed.23 Thus, 
the reduction in DLco detected may be ascribed to the vascular 
changes that characterise the disease. Vascular changes under-
lying DLco reduction have been documented at autopsy studies. 
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In 1978, Young and Mark found intimal and medial hyperplasia 
affecting pulmonary arteries of all sizes, with arteries of different 
diameter affected to a comparable degree.24 Most patients (82%) 
had moderate to marked arterial disease.24 On lung biopsies, 
despite differences in fibrosis severity, the vascular distribution of 
the lesions in idiopathic pulmonary fibrosis (IPF) and SSc is very 
similar and characterised by ablation of vessels in fibrotic lung 
portions and increased distance between vessels and airspaces.25 
However, biopsies results refer only to the limited amount of 
removed fibrotic tissue, whereas correlations between structure 
and function are necessarily compelled by regional variations in 
disease activity and severity.
Recent technological advances in CT image post processing 
have led to the development of non- invasive and fully auto-
mated quantitative imaging tools to analyse the whole pulmo-
nary vasculature without contrast media and repeated ionising 
exposure during injection.4–7 In a recent study, it has been shown 
that in patients with SSc, DLco is associated with CT changes 
of pulmonary vascular morphology. In particular, DLco reduc-
tion was associated with biomarkers quantifying the dilation 
of proximal vessels and the number of capillaries.5 Another 
advanced tool (CALIPER) enabled the quantification of PVV in 
IPF, showing significant negative correlation with DLco.26 In the 
present study, we used the same tool to quantify PVV in patients 
with SSc to better define differences in pulmonary vasculature 
in relation to different gas exchange and functional presenta-
tion. We found PVV to be increased both in iDLco and restricted 
groups in comparison to the normal group. The observed 
increase in PVV confirms, even if of lower degree, that observed 
in IPF in a previous study (PVV/LV=5%).26 It has been hypoth-
esised that the PVV signal in IPF could represent a misclassified 
reticular pattern.27 Our results are not supportive of this hypoth-
esis. Indeed, the different distribution of PVV/LV and reticular 
pattern across lung thirds, with the former mainly located in the 
middle third and in central regions and the latter in the lower 
third and in peripheral regions, corresponds to our knowledge 
of distribution of ILD patterns in patients with SSc at qualitative 
analysis of chest CT scans and with those studies demonstrating 
the unaffected mechanisms of redistribution of perfusion to less 
affected thirds.28–30 Furthermore, in patients with iDLco, we 
observed a significant increase in PVV with respect to normal, 
despite a not significant increase in reticular pattern.
In our patients, the increase in PVV paralleled by the decrease 
in DLco could be explained by the redistribution of perfusion 
to well- ventilated lung regions or a concomitant aberrant angio-
genesis, as demonstrated in IPF.31 32 Unlike IPF, the mecha-
nisms of redistribution of perfusion are unimpaired in patients 
with SSc, as demonstrated both functionally and radiologically 
on magnetic resonance imaging.29 30 However, DLco may not 
be preserved when reduction in patency of some pulmonary 
vessels coexists with a compensatory dilation of the unaffected 
vasculature. Disproportionate reduction in membrane diffu-
sion (DM) relative to capillary blood volume (Vc) may occur 
due to modifications of vascular geometry.23 33 Similarly to IPF, 
the increase in PVV could also be due to a concomitant aber-
rant angiogenesis.25 31 32 34 Indeed, patients with SSc are more 
prone to angiogenesis than control subjects as they have higher 
levels of circulating angiogenic factors (eg, vascular endothelial 
growth factor),35 cutaneous vessel formation36 and an increased 
rate of endothelial cell proliferation in biopsied lung portions.25 
Nonetheless, the increased rate of endothelial proliferation 
found in lung biopsies of patients with SSc would not be neces-
sarily caused by new vessel formation, but instead it could be an 
expression of increased vascular turnover as a response to an 
ongoing insult.25 Thus, the increased rate of endothelial prolif-
eration may not exclude a mere redistribution of lung perfusion 
coupled with an accelerated vascular turnover following the 
chronic vascular insult. The CT- derived parameter PVV cannot 
be determinant to solve this issue. PVV is not a specific indi-
cator of new vessels formation and it cannot distinguish the 
arterial wall from its content and, consequently, arterial wall 
thickening from increased blood volume. However, the analysis 
of regional distribution of PVV/LV and reticular pattern could 
help in the understanding of this pathophysiological aspect. The 
opposed distribution of PVV/LV and reticular pattern between 
central and peripheral regions across lung thirds may support 
the hypothesis of redistribution of blood flow in the regions and 
thirds less affected by ILD, where vessels can still maintain their 
ability to be recruited. The smaller association found between 
PVV/LV and ILD_Ext in the lower third in respect to the other 
two thirds may also support this hypothesis.
In IPF, PVV is a predictive biomarker of mortality4 and its 
prognostic role in SSc needs further investigation in longitu-
dinal studies, especially to better characterise CT subgroups 
with different prognosis within the iDLco group, as previously 
observed in a clinical study.19 Similarly to data reported in 
the literature, this group is characterised by an increase in the 
FVC/DLco ratio in comparison to both restricted and normal 
groups.3 19 Although an FVC/DLco ratio greater than 1.4 was 
found to be the best predictor for isolated PAH, only some 
patients with iDLco develop PAH and the remaining have a 
better prognosis than those presenting with a restrictive func-
tional pattern.19 Thorough evaluation of PVV in a larger iDLco 
group may help stratifying subgroups with different prognosis. 
Nonetheless, DLco (silent in 30% of cases with lung fibrosis) has 
a lower sensitivity than diffusing lung capacity for nitric oxide 
(DLno) in detecting diffusion limitation.23 This may hamper our 
ability to define the group of patients with iDLco, being many of 
them possibly defined as ‘normal’.23 Future studies using DLno 
instead of DLco to assess diffusing capacity might improve the 
definition of the functional presentation of patients with SSc and 
therefore their prognosis.
Our study has some limitations. First, the cross- sectional 
nature precluded the opportunity of assessing longitudinal 
changes in PVV among groups of patients and its prognostic role. 
A longitudinal analysis might provide important information to 
better understand the clinical relevance of vascular changes char-
acteristics in patients with SSc. Second, PVV cannot distinguish 
pulmonary arteries from veins. A more accurate investigation 
with further software development would be a relevant step 
forward in the pathophysiological study of vascular changes in 
SSc. Third, we did not enrol all patients with SSc presenting to 
our institution, but only those undergoing a chest CT scan for 
the evaluation or detection of ILD. This approach could have 
excluded patients with silent initial pulmonary vascular changes. 
Finally, spirometry gating at CT is time consuming and far to be 
implemented in the high flux of CT examinations of the routine 
radiological practice. The spirometry- gated approach was 
adopted in the present study for research purposes to avoid bias 
in quantification of lung patterns of disease. Moreover, no rele-
vant improvement in correlation values was observed in respect 
to a previous study performed without gating.37
In conclusion, our results have disclosed that patients with 
SSc have an increased PVV/LV, as assessed on CT scan, paral-
leled by a decrease in DLco. This increase in PVV/LV was even 
more pronounced when DLco reduction was coupled with FVC 
decrease. The PVV/LV was the only independent predictor 
of DLco at the multivariate analysis and its distribution was 
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different from that of reticular pattern. The associations found 
across lung thirds between PVV/LV and ILD extent may support 
the hypothesis of a redistribution of pulmonary flow in thirds 
less affected by ILD. Further studies in larger multicentric 
cohorts are warranted to confirm these results and to assess the 
individual contribution of arterial and venous pulmonary vessels 
to the pathophysiology of SSc vascular involvement. Further 
advances in this field may help in stratifying patients to tailor 
different therapeutic approaches according to the severity and 
the distribution of pulmonary vascular changes.
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